论文期刊

取消

高级检索

检索历史清除

首页> Clinical therapeutics> Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

导出 LinkOut

翻译打印收藏纠错

作者： Richard,Haynes ^[1] ; Elsa,Valdes-Marquez ^[2] ; Jemma C,Hopewell ^[2] ; Fang,Chen ^[2] ; Jing,Li ^[3] ; Sarah,Parish ^[4] ; Martin J,Landray ^[4] ; Jane,Armitage ^[4] ; HPS2-THRIVE Collaborative Group ; HPS2-THRIVE Writing Committee members ; HPS2-THRIVE Steering Committee members

作者单位： MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. Electronic address: richard.haynes@ndph.ox.ac.uk. ^[1] Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. ^[2] National Centre for Cardiovascular Disease, Beijing, China. ^[3] MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. ^[4]

关键词 adverse effects bleeding cardiovascular disease infection niacin

主题词心血管疾病(Cardiovascular Diseases);迟效制剂(Delayed-Action Preparations);糖尿病(Diabetes Mellitus);双盲法(Double-Blind Method);药物疗法, 联合(Drug Therapy, Combination);血脂异常(Dyslipidemias);女(雌)性(Female);出血(Hemorrhage);人类(Humans);降血脂药物(Hypolipidemic Agents);发病率(Incidence);吲哚类(Indoles);男(雄)性(Male);尼克酸(Niacin)

DOI 10.1016/j.clinthera.2019.06.012

PMID 31447131

发布时间 2021-01-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览9

Clinical therapeutics

Clinical therapeutics

2019年41卷9期

1767-1777页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览9

Clinical therapeutics

点击下载本期目录封面

Clinical therapeutics

2019年41卷9期

1767-1777页

相关期刊

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷